Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Verastem Expression of Interest Call VS-4718: FAK/PYK2 kinase inhibitor VS-4718, is an oral small molecule FAK/PYK2 kinase inhibitor. Verastem are interested to review expressions of interest with a strong scientific rational for novel combinations (including immune checkpoint inhibitors, other immunoâoncology agents and targeted agents of other classes). Of note, VS-4718 is able to cross the blood brain barrier, offering opportunity for Glioblastomas and other brain cancers. Please refer to the non-confidential data package for further information on VS- 4718. VS-5584: PI3K/mTOR kinase inhibitor VS-5584, is a small molecule PI3K/mTOR kinase inhibitor. Verastem are interested to review expressions of interest with a strong scientific rational for novel combinations and have expressed a particular interest in the following areas: - BTK inhibitor combination in lymphoma/leukemia (e.g. DLBCL) - Combination with cisplatin + XRT in cervical cancer - Combination with androgen receptor blockade in prostate cancer - Combination with platinum in BRCA mutant cancers (ovarian ca post PARPi, TNBC etc.) - Combination with weekly paclitaxel in endometrial cancer Please refer to the non-confidential data package for further information on VS- 5584.